At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
The purpose of this study is to assess the safety and effectiveness of partial breast radiation therapy given over a three-day period (three weekdays in a row) in women with ductal carcinoma in situ (DCIS) or early-stage invasive breast cancer after lumpectomy. Women who are not in a research study usually receive radiation therapy to the whole breast over three weeks or receive partial breast irradiation over a five- to ten-day period.
-
Unfavorable intermediate-risk prostate cancers have not spread beyond the prostate but have a chance of coming back. They are usually treated with surgery or radiation therapy, with or without hormonal therapy. One of the more common standard treatment approaches is hormonal therapy called androgen deprivation therapy (ADT), which reduces the levels of male sex hormones, followed by external beam radiation therapy (EBRT) to the prostate and nearby lymph nodes.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
- A Phase 2 Study of Isatuximab to Treat Low Blood Cell Counts in People With Blood Cancer Who Had a Stem Cell Transplant from a Donor
Full Title Open-Label, Phase II Trial of Isatuximab for Patients with Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Purpose
Researchers want to see if isatuximab helps improve immune cytopenias (ICs) caused by a donated stem cell transplant. A transplant from a donor is called an allogeneic hematopoietic cell transplant (allo-HCT). People with blood cancers often receive an allo-HCT. ICs are abnormally low blood cell counts that can happen after an allo-HCT. They cause people to need blood or platelet transfusions. Platelets are blood cells needed for clotting. Researchers in this study will see if isatuximab can improve ICs and lessen the need for blood or platelet transfusions.
Isatuximab targets a protein in the body that can cause tumors to grow and also make the immune system overactive. Isatuximab may help protect healthy cells from damage. It is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have low blood cell counts after having allo-HCT.
- Have had your transplant at least 45 days before getting isatuximab.
- Have blood cell counts that are low even with standard treatment for ICs.
- Be in remission from the blood cancer for which you had an allo-HCT.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Michael Scordo’s office at 646-608-3771.
Protocol
23-119Phase
Phase II (phase 2)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05873205ClinicalTrials.gov
-
Researchers want to see if AAA617 can slow the growth of advanced prostate cancer. They also want to learn if this treatment can delay the need to start hormonal therapy. Treatment with AAA617 will be compared to observation (no treatment other than standard targeted radiation therapy).
-
Researchers are doing this study is to find the highest dose of a new cell therapy for people with leukemia. The people in this study have acute myelogenous leukemia (AML) that keeps growing even after treatment. They will get the new treatment with atezolizumab, an immune-boosting therapy.
-
Researchers in this study are assessing the drug ACR-368 alone and in combination with increasing doses of low-dose gemcitabine in people with ovarian, endometrial, or urothelial (bladder) cancer that has come back despite prior treatment. ACR-368 works by stopping cancer cells from repairing damage to themselves and their DNA (genes). Gemcitabine damages the DNA inside cancer cells and prevents the cells from multiplying.
-
Researchers want to see if zongertinib is safe and works well to treat advanced solid tumors. The people in this study have solid tumors that metastasized (spread). The tumors contain an abnormal HER2 protein (mutation) or too much HER2 (overexpression/amplification). HER2 promotes the growth of cancer cells.
-
Roginolisib works by blocking a protein called PI3K-delta. By blocking this protein, roginolisib may strengthen your immune system's ability to fight cancer cells. It is taken orally (by mouth).